Moleculin Biotech, Inc. (MBRX)

Market Cap	14.56M
Revenue (ttm)	n/a
Net Income (ttm)	-21.76M
Shares Out	14.00M
EPS (ttm)	-6.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	367,920
Open	1.060
Previous Close	1.050
Day's Range	1.010 - 1.050
52-Week Range	0.398 - 6.090
Beta	1.94
Analysts	Strong Buy
Price Target	17.33 (+1,566.35%)
Earnings Date	Mar 21, 2025

About MBRX

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription fact...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 2, 2016
• Employees: 18
• Stock Exchange: NASDAQ
• Ticker Symbol: MBRX
• Website: https://moleculin.com

Analyst Forecast

According to 3 analysts, the average rating for MBRX stock is "Strong Buy." The 12-month stock price forecast is $17.33, which is an increase of 1,566.35% from the latest price.

Price Target

$17.33

(1,566.35% upside)

Analyst Consensus: Strong Buy